BidaskClub Downgrades Inogen (NASDAQ:INGN) to Sell

BidaskClub downgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a research report released on Saturday, January 6th.

A number of other analysts have also issued reports on the company. Needham & Company LLC lifted their target price on Inogen from $108.00 to $125.00 and gave the stock a strong-buy rating in a research report on Wednesday, November 8th. Zacks Investment Research raised Inogen from a hold rating to a buy rating and set a $131.00 target price on the stock in a research report on Thursday, November 9th. Piper Jaffray Companies reissued a hold rating and issued a $90.00 price objective on shares of Inogen in a report on Tuesday, September 12th. Finally, Leerink Swann reissued an outperform rating and issued a $120.00 price objective (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $102.71.

Shares of Inogen (INGN) traded up $0.42 during trading on Friday, reaching $115.59. The company had a trading volume of 177,929 shares, compared to its average volume of 135,002. Inogen has a 52-week low of $62.69 and a 52-week high of $130.05. The firm has a market capitalization of $2,403.64, a PE ratio of 93.98, a P/E/G ratio of 3.90 and a beta of 1.13.

Inogen (NASDAQ:INGN) last issued its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.04. The firm had revenue of $69.00 million for the quarter, compared to analysts’ expectations of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The firm’s revenue for the quarter was up 26.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.25 earnings per share. equities research analysts anticipate that Inogen will post 1.19 EPS for the current fiscal year.

In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $94.07, for a total value of $1,316,980.00. Following the completion of the sale, the director now directly owns 7,808 shares in the company, valued at $734,498.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Byron Myers sold 35,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $116.77, for a total value of $4,086,950.00. Following the completion of the sale, the executive vice president now owns 48,600 shares of the company’s stock, valued at $5,675,022. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 81,500 shares of company stock valued at $9,267,695. Insiders own 5.31% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in shares of Inogen by 1.9% in the second quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock valued at $205,207,000 after buying an additional 39,752 shares in the last quarter. Vanguard Group Inc. raised its stake in Inogen by 24.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after purchasing an additional 301,737 shares during the period. Koch Industries Inc. raised its stake in Inogen by 19,485.8% during the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after purchasing an additional 653,747 shares during the period. Dimensional Fund Advisors LP raised its stake in Inogen by 3.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock valued at $49,572,000 after purchasing an additional 17,111 shares during the period. Finally, State Street Corp raised its stake in Inogen by 6.8% during the 2nd quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock valued at $40,619,000 after purchasing an additional 27,250 shares during the period.

TRADEMARK VIOLATION NOTICE: This story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/01/13/inogen-ingn-lowered-to-sell-at-bidaskclub-updated.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply